FAREVA employs 13,000 people distributed in 43 production sites located in 13 countries in EMEA and the Americas. 18 of the FAREVA sites (including the latest acquisitions) are dedicated to pharmaceutical activities.

FAREVA is a leading global pharmaceutical CDMO with industry leading capabilities in the development and manufacturing of a large range of Drug Products and Active Pharmaceutical Ingredients (APIs).

FAREVA's capabilities support a broad range of therapeutic areas including vaccines, oncology, antibiotics, biologics, OTC, animal health, ophthalmic products. Fareva offers different technologies: injectables (lyophilized, solution, suspension, vial, ampoules, pre-filled syringes), unidoses and multidoses BFS, solids (tablets, hard capsules, powders), semi-solids (cream, gel suppositories) and liquids (oral and external, sprays, aerosols...).

FAREVA's API division has operations in 3 European sites located in France and Germany, and these sites are EMA and US-FDA inspected. FAREVA has industry leading expertise in the areas of development & optimization of complex, multi-step synthesis of APIs & Advanced Intermediates. The group has niche technologies for high potent APIs (HPAPIs) down to the OEB-6 level, aseptic crystallization (sterile APIs), Spray Drying, cryogenic reactions, hydrogenation, steroid chemistry, and PSD and polymorph control, with volumes ranging from a few kgs to multi tons production. FAREVA API is able to support our customers from early clinical phase programs, requiring small scale manufacturing, process optimization and scale-up, to launch and commercial phases. FAREVA is also the first and only company in the world to receive SafeBridge Certification to handle both high potent drug substance and drug product at the same facility.
All sites are state of the art cGMP, FDA / EU approved and our packaging sites are fully equipped for serialization and aggregation.

You can get additional information by reading these articles!:
https://www.pharmasalmanac.com/articles/streamlining-process-validation-for-drug-substance-manufacturing https://www.pharmasalmanac.com/articles/expanding-sterile-crystallization-capabilities-to-meet-rising-customer-demand https://www.pharmasalmanac.com/articles/should-you-choose-a-commercial-hpapi-manufacturer-for-your-clinical-program https://www.pharmasalmanac.com/articles/simplifying-the-supply-chain-with-large-volume-western-cdmo-partners https://www.pharmasalmanac.com/articles/a-successful-approach-for-managing-unexpected-increases-in-potency-for-hpapis https://www.pharmasalmanac.com/articles/innovative-approach-to-process-development https://www.pharmasalmanac.com/articles/providing-solutions-at-fair-value-a-spray-drying-case-study https://www.pharmasalmanac.com/articles/streamlining-highly-potent-drug-commercialization